| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NRD2356 |
| P8608 | Fatcat ID | release_zfdhwnvipbd37dmddipyais7cq |
| P932 | PMC publication ID | 4455967 |
| P698 | PubMed publication ID | 19300460 |
| P2093 | author name string | Hugh Rosen | |
| David Marsolais | |||
| P2860 | cites work | Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate | Q22010773 |
| Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform | Q22253469 | ||
| Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1 | Q24314828 | ||
| Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation | Q24629370 | ||
| Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions | Q24646942 | ||
| Role of ABCC1 in export of sphingosine-1-phosphate from mast cells | Q24671687 | ||
| Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement | Q24671831 | ||
| Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors | Q28200828 | ||
| International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature | Q28201589 | ||
| Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist | Q28215689 | ||
| Sphingosine-1-phosphate prevents tumor necrosis factor-{alpha}-mediated monocyte adhesion to aortic endothelium in mice | Q28239258 | ||
| Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor | Q28262554 | ||
| Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN | Q28297849 | ||
| Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation | Q28588671 | ||
| Efficacy and safety of recombinant human activated protein C for severe sepsis | Q29547839 | ||
| The acute respiratory distress syndrome | Q29615140 | ||
| Multiple sclerosis | Q29616022 | ||
| Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists | Q29618071 | ||
| Sphingosine 1-phosphate analogs as receptor antagonists | Q30435361 | ||
| Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists | Q30442170 | ||
| Diverse and potent chemokine production by lung CD11bhigh dendritic cells in homeostasis and in allergic lung inflammation | Q30442651 | ||
| Regulation of inflammatory vascular damage | Q33843576 | ||
| Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. | Q51683065 | ||
| Sphingosine-1-phosphate and lysophosphatidic acid stimulate endothelial cell migration. | Q52538793 | ||
| Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. | Q52578077 | ||
| Sphingosine 1-phosphate inhibits ischemia reperfusion injury following experimental lung transplantation. | Q53563061 | ||
| S1P(1)-selective agonist, SEW2871, ameliorates ischemic acute renal failure. | Q54611404 | ||
| Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. | Q55470660 | ||
| Sphingosine kinase 1 regulates pro-inflammatory responses triggered by TNFalpha in primary human monocytes | Q56749578 | ||
| Drug delivery to damaged brain | Q57318252 | ||
| Transactivation of Sphingosine 1-Phosphate Receptors Is Essential for Vascular Barrier Regulation | Q57372523 | ||
| Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes | Q57952121 | ||
| Sphingosine-1-Phosphate/Sphingosine Kinase Pathway Is Involved in Mouse Airway Hyperresponsiveness | Q59247475 | ||
| Treatment of acute renal failure | Q77682455 | ||
| Homo- and hetero-dimerization of LPA/S1P receptors, OGR1 and GPR4 | Q79194051 | ||
| Sphingosine 1-phosphate interferes on the differentiation of human monocytes into competent dendritic cells | Q79525927 | ||
| Lysophospholipids increase IL-8 and MCP-1 expressions in human umbilical cord vein endothelial cells through an IL-1-dependent mechanism | Q79776833 | ||
| Normal acute and chronic inflammatory responses in sphingosine kinase 1 knockout mice | Q80022540 | ||
| High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor | Q80284338 | ||
| Sphingosine 1-phosphate (S1P) inhibits monocyte-endothelial cell interaction by regulating of RhoA activity | Q81159290 | ||
| Niessen F, Furlan-Freguia C, Fernandez JA, Mosnier LO, Castellino FJ, Weiler H, Rosen H, Griffin JH, Ruf W. Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. Blood. 2009;113(12):2859-2866 | Q84102149 | ||
| Blood-brain barrier delivery | Q34001715 | ||
| Enzymes of sphingolipid metabolism: from modular to integrative signaling | Q34220989 | ||
| Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. | Q34227743 | ||
| Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases | Q34234281 | ||
| Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation | Q34434772 | ||
| Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. | Q34546048 | ||
| Oral fingolimod (FTY720) for relapsing multiple sclerosis | Q34565985 | ||
| Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis | Q34581700 | ||
| FTY720-phosphate is dephosphorylated by lipid phosphate phosphatase 3. | Q34635490 | ||
| Sphingosine-1-phosphate and lipid phosphohydrolases | Q34691418 | ||
| Homodimerization and heterodimerization of S1P/EDG sphingosine-1-phosphate receptors | Q34691450 | ||
| In vivo roles of lysophospholipid receptors revealed by gene targeting studies in mice | Q34691533 | ||
| Sphingosine 1-phosphate as a therapeutic agent | Q34802499 | ||
| The sphingolipid transporter spns2 functions in migration of zebrafish myocardial precursors | Q34901297 | ||
| Sphingosine 1-phosphate, a diffusible calcium influx factor mediating store-operated calcium entry. | Q35503361 | ||
| Structural and functional characteristics of S1P receptors. | Q35839016 | ||
| A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma | Q35894958 | ||
| In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights | Q35923020 | ||
| Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. | Q35925633 | ||
| Statins and the response to myocardial injury | Q36131323 | ||
| Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network | Q36184401 | ||
| Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management | Q36261456 | ||
| Development of the blood-brain barrier: a historical point of view | Q36377906 | ||
| Blood-brain barrier dysfunction and recovery | Q36426867 | ||
| Endothelial cell dysfunction, injury and death. | Q36603038 | ||
| Regulation and functional roles of sphingosine kinases | Q36715339 | ||
| Tipping the gatekeeper: S1P regulation of endothelial barrier function | Q36727643 | ||
| Pathogenesis of avian flu H5N1 and SARS. | Q36728250 | ||
| Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology | Q36846525 | ||
| Randomized clinical trial of activated protein C for the treatment of acute lung injury | Q36889970 | ||
| Local not systemic modulation of dendritic cell S1P receptors in lung blunts virus-specific immune responses to influenza | Q36952932 | ||
| Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis | Q36981896 | ||
| Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review | Q37014196 | ||
| Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality | Q37142196 | ||
| Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor | Q37193113 | ||
| Quantitative proteomics analysis of human endothelial cell membrane rafts: evidence of MARCKS and MRP regulation in the sphingosine 1-phosphate-induced barrier enhancement | Q37196996 | ||
| Sphingosine-1-phosphate in the regulation of vascular tone: a finely tuned integration system of S1P sources, receptors, and vascular responsiveness | Q37231441 | ||
| Cell adhesion molecules and ischemic stroke | Q37282898 | ||
| Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP(B2)/EDG-5 and S1P(3)/LP(B3)/EDG-3. | Q38289340 | ||
| Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase | Q38342964 | ||
| Role of sphingosine-1 phosphate in the enhancement of endothelial barrier integrity by platelet-released products | Q38356959 | ||
| S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate | Q40405662 | ||
| The immune modulator FTY720 targets sphingosine 1-phosphate receptors | Q40736684 | ||
| Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient | Q42026885 | ||
| Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions | Q42090948 | ||
| Deafness and stria vascularis defects in S1P2 receptor-null mice. | Q42507950 | ||
| The suppressive effect of sphingosine 1-phosphate on monocyte-endothelium adhesion may be mediated by the rearrangement of the endothelial integrins alpha(5)beta(1) and alpha(v)beta(3). | Q42510506 | ||
| Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets | Q42826228 | ||
| Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses | Q43746398 | ||
| S1P induces FA remodeling in human pulmonary endothelial cells: role of Rac, GIT1, FAK, and paxillin | Q44249721 | ||
| Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment | Q44370378 | ||
| Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate | Q44734550 | ||
| Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury | Q44799601 | ||
| Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney | Q44916450 | ||
| Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging | Q44955081 | ||
| Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. | Q44987202 | ||
| Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury | Q44999171 | ||
| Attenuation of shock-induced acute lung injury by sphingosine kinase inhibition | Q45173949 | ||
| KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts | Q45218848 | ||
| Alveolar macrophages contribute to alveolar barrier dysfunction in ventilator-induced lung injury | Q46077509 | ||
| Sphingosine 1-phosphate (S1P) signaling is required for maintenance of hair cells mainly via activation of S1P2. | Q46117845 | ||
| A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model | Q46174987 | ||
| Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate | Q46494392 | ||
| Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury | Q46503010 | ||
| S1P1-selective agonist SEW2871 exacerbates reperfusion arrhythmias | Q46547671 | ||
| FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage | Q46550100 | ||
| Sphingosine 1-phosphate receptors regulate chemokine-driven transendothelial migration of lymph node but not splenic T cells. | Q46664082 | ||
| Selective activation of G alpha i mediated signalling of S1P3 by FTY720-phosphate. | Q46722992 | ||
| The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo | Q46741854 | ||
| Neutrophil sphingosine 1-phosphate and lysophosphatidic acid receptors in pneumonia | Q46752140 | ||
| Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes | Q46815005 | ||
| Mouse sphingosine kinase isoforms SPHK1a and SPHK1b differ in enzymatic traits including stability, localization, modification, and oligomerization | Q46861688 | ||
| FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. | Q46903743 | ||
| A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice. | Q46979859 | ||
| Modulation of P-glycoprotein function by sphingosine kinase-1 in brain endothelial cells | Q48266093 | ||
| Erythrocytes store and release sphingosine 1-phosphate in blood. | Q51084957 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 297-307 | |
| P577 | publication date | 2009-03-20 | |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules | |
| P478 | volume | 8 |
| Q52645793 | 19F/18F exchange synthesis for a novel [18F]S1P3-radiopharmaceutical. |
| Q33598692 | 4-Methoxy-N-[2-(trifluoromethyl)biphenyl-4-ylcarbamoyl]nicotinamide: A Potent and Selective Agonist of S1P1. |
| Q93177027 | A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD |
| Q89823404 | A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models |
| Q35868052 | A potent and selective C-11 labeled PET tracer for imaging sphingosine-1-phosphate receptor 2 in the CNS demonstrates sexually dimorphic expression. |
| Q47679381 | A review of bioanalytical quantitative methods for selected sphingosine 1-phosphate receptor modulators |
| Q46225129 | A sphingosine-1-phosphate receptor 1 agonist inhibits tertiary lymphoid tissue reactivation and hypersensitivity in the lung |
| Q33784217 | A sphingosine-1-phosphate receptor type 1 agonist, ASP4058, suppresses intracranial aneurysm through promoting endothelial integrity and blocking macrophage transmigration |
| Q30303094 | Abluminal stimulation of sphingosine 1-phosphate receptors 1 and 3 promotes and stabilizes endothelial sprout formation |
| Q33646637 | An Evolutionarily Conserved Arginine Is Essential for Tre1 G Protein-Coupled Receptor Function During Germ Cell Migration in Drosophila melanogaster |
| Q58604755 | An update on sphingosine-1-phosphate receptor 1 modulators |
| Q54646109 | Antiangiogenic agents and targets: A perspective |
| Q35683275 | Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing. |
| Q30425227 | Characterization of a sphingosine 1-phosphate receptor antagonist prodrug |
| Q36386459 | Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. |
| Q37831798 | Contribution of platelets to tumour metastasis. |
| Q48455938 | Differential modulation of S1PR(1-5) and specific activities of SphK and nSMase in pulmonary and cerebral tissues of rats exposed to hypobaric hypoxia |
| Q33598794 | Discovery of AMG 369, a Thiazolo[5,4-b]pyridine Agonist of S1P1 and S1P5. |
| Q33598742 | Discovery of a Potent, S1P3-Sparing Benzothiazole Agonist of Sphingosine-1-Phosphate Receptor 1 (S1P1) |
| Q24616691 | Discovery, design and synthesis of novel potent and selective sphingosine-1-phosphate 4 receptor (S1P₄-R) agonists |
| Q33899493 | Discovery, design and synthesis of the first reported potent and selective sphingosine-1-phosphate 4 (S1P4) receptor antagonists |
| Q24631044 | Discovery, synthesis and SAR analysis of novel selective small molecule S1P4-R agonists based on a (2Z,5Z)-5-((pyrrol-3-yl)methylene)-3-alkyl-2-(alkylimino)thiazolidin-4-one chemotype |
| Q30366282 | Drugging sphingosine kinases. |
| Q89793251 | Emerging treatments for inflammatory bowel disease |
| Q37950457 | Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs |
| Q93099625 | Expression of sphingosine kinase 1 and sphingosine 1-phosphate receptor 3 in malaria-associated acute lung injury/acute respiratory distress syndrome in a mouse model |
| Q36404218 | Fingolimod (FTY720-P) Does Not Stabilize the Blood-Brain Barrier under Inflammatory Conditions in an in Vitro Model |
| Q34618474 | Fingolimod for relapsing multiple sclerosis: an update. |
| Q39252582 | Fingolimod-associated amenorrhea: a report of three cases |
| Q38639875 | Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis |
| Q33816773 | Functional promoter variants in sphingosine 1-phosphate receptor 3 associate with susceptibility to sepsis-associated acute respiratory distress syndrome |
| Q28073125 | Glycocalyx and its involvement in clinical pathophysiologies |
| Q37072894 | Identification of a metabolizing enzyme in human kidney by proteomic correlation profiling |
| Q46572613 | Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease |
| Q33881977 | Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis |
| Q38214959 | Mechanistic explanation for platelet contribution to cancer metastasis |
| Q34458426 | Modulation of Chemokines and Allergic Airway Inflammation by Selective Local Sphingosine-1-phosphate Receptor 1 Agonism in Lungs |
| Q55007993 | Next generation of small molecules in inflammatory bowel disease. |
| Q38744708 | Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases |
| Q90258770 | Novel Non-biologic Targets for Inflammatory Bowel Disease |
| Q36484486 | Novel selective allosteric and bitopic ligands for the S1P(3) receptor. |
| Q90414448 | Overexpression of Sphingosine Kinase-1 and Sphingosine-1-Phosphate Receptor-3 in Severe Plasmodium falciparum Malaria with Pulmonary Edema |
| Q41653767 | PET Imaging Study of S1PR1 Expression in a Rat Model of Multiple Sclerosis |
| Q28555184 | Pathophysiological Consequences of a Break in S1P1-Dependent Homeostasis of Vascular Permeability Revealed by S1P1 Competitive Antagonism |
| Q37980790 | Perspectives on immunomodulation early in life. |
| Q47430919 | Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P₁ Receptor Modulator in Healthy Subjects. |
| Q35130512 | Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system |
| Q37978478 | Pharmacological targets in the renal peritubular microenvironment: implications for therapy for sepsis-induced acute kidney injury |
| Q48299333 | Pharmacophore-based design of novel oxadiazoles as selective sphingosine-1-phosphate (S1P) receptor agonists with in vivo efficacy |
| Q38794279 | Ponesimod, a selective sphingosine 1-phosphate (S1P1) receptor modulator for autoimmune diseases: review of clinical pharmacokinetics and drug disposition |
| Q34728125 | Predictability of peripheral lymphocyte reduction of novel S1P1 agonists by in vitro GPCR signaling profile |
| Q35107430 | Purification and identification of activating enzymes of CS-0777, a selective sphingosine 1-phosphate receptor 1 modulator, in erythrocytes |
| Q37929004 | Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm |
| Q41870066 | Reassessment of the pharmacology of Sphingosine-1-phosphate S1P3 receptor ligands using the DiscoveRx PathHunter™ and Ca2+ release functional assays. |
| Q41812316 | Roles of sphingosine-1-phosphate signaling in angiogenesis |
| Q35175894 | SAR analysis of innovative selective small molecule antagonists of sphingosine-1-phosphate 4 (S1P₄) receptor |
| Q40498932 | Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy |
| Q52851166 | Scintillation Proximity Assay to Detect the Changes in Cellular Dihydrosphingosine 1-Phosphate Levels. |
| Q91606909 | Serum sphingosine-1-phosphate levels and Sphingosine-1-Phosphate gene polymorphisms in acute respiratory distress syndrome: a multicenter prospective study |
| Q21296721 | Sphingolipids: a potential molecular approach to treat allergic inflammation |
| Q38669047 | Sphingomimetic multiple sclerosis drug FTY720 activates vesicular synaptobrevin and augments neuroendocrine secretion |
| Q38762603 | Sphingosine 1-phosphate receptor 1 agonists: a patent review (2013-2015). |
| Q28288034 | Sphingosine 1-phosphate receptor agonists: a patent review (2010-2012) |
| Q42149287 | Sphingosine analogue AAL-R increases TLR7-mediated dendritic cell responses via p38 and type I IFN signaling pathways |
| Q91801206 | Sphingosine-1-Phosphate Facilitates Skin Wound Healing by Increasing Angiogenesis and Inflammatory Cell Recruitment with Less Scar Formation |
| Q55564395 | Sphingosine-1-Phosphate-Specific G Protein-Coupled Receptors as Novel Therapeutic Targets for Atherosclerosis. |
| Q34474363 | Sphingosine-1-phosphate and immune regulation: trafficking and beyond |
| Q33498660 | Sphingosine-1-phosphate as an amphipathic metabolite: its properties in aqueous and membrane environments |
| Q37479030 | Sphingosine-1-phosphate effects on the inner wall of Schlemm's canal and outflow facility in perfused human eyes |
| Q36539650 | Sphingosine-1-phosphate receptor-3 is a novel biomarker in acute lung injury |
| Q30432808 | Stereochemistry-activity relationship of orally active tetralin S1P agonist prodrugs. |
| Q30486707 | The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors |
| Q51715097 | The autonomic balance predicts cardiac responses after the first dose of fingolimod. |
| Q36011196 | The outs and the ins of sphingosine-1-phosphate in immunity |
| Q37724167 | The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides |
| Q37928817 | The role of sphingolipids in respiratory disease |
| Q36361669 | The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate |
| Q27316144 | The sphingolipid receptor S1PR2 is a receptor for Nogo-a repressing synaptic plasticity |
| Q38915115 | Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism |
| Q34527281 | Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer |
| Q57158941 | Treating Influenza Infection, From Now and Into the Future |
| Q35089714 | Treatment with a sphingosine analog after the inception of house dust mite-induced airway inflammation alleviates key features of experimental asthma. |
| Q33653315 | Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection |
| Q34474335 | Understanding the addiction cycle: a complex biology with distinct contributions of genotype vs. sex at each stage. |
Search more.